leisure time -WSS

leisure time

author：comprehensive 2025-08-23 05:00:53 - browse：3622

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： 7 more heat

explore

WSS

Virtual Event: March of the Biosimilars

Awakening the world to the whoosh: A patient's crusade

Future doctors should be trained to promote social change

Plastic surgeons increase patient psychiatric screenings

Neuroscience’s long legacy of racism

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stanford president faces new allegations over 1999 paper

Alkermes shareholders re

Neuroscience’s long legacy of racism

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Bluebird, CVS, Contineum

United colonoscopy coverage change 'may cost lives,' doctors say

App could help diagnose ear infections more accurately — and at home

Trump demands the U.S. pay no more for drugs than other countries … again

Why Congress must ban federal programs from using QALYs

hotspot

Leading voice in opioid treatment defends methadone clinic system

Texas Department of Public Safety speaks out on migrant abuse allegations

Stop the failed accountable care organization experiment

Why Congress must ban federal programs from using QALYs

Leading voice in opioid treatment defends methadone clinic system

UnitedHealth increases loan offers after Change Healthcare outage

entertainment

Wikipedia

explore

leisure time